La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Shandong Weigao Group Medical Polymer Gestion
Gestion contrôle des critères 3/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Rinan Cong
Directeur général
CN¥4.0m
Rémunération totale
| Pourcentage du salaire du PDG | 42.1% |
| Durée du mandat du directeur général | no data |
| Propriété du PDG | 0.05% |
| Durée moyenne d'occupation des postes de direction | 2.2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 2.2yrs |
Mises à jour récentes de la gestion
Recent updates
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target
Aug 30
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk
Jun 25Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return
Jun 23Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year
May 31We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope
May 22Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Apr 23Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results
Mar 28Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon
Jan 09Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 22Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?
Nov 10Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Oct 05Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing
Aug 01Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?
Jul 19Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Jun 22Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?
Jun 09The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Apr 27Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Mar 17A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Feb 27Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes
Jan 18Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Dec 12Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate
Nov 29Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today
Nov 14Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year
Oct 03The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Sep 21Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt
Sep 05Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price
Aug 23Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors
Aug 08There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital
Jun 22Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year
Jun 08An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued
May 16Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
May 03Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher
Mar 17Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?
Jan 28Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?
Jan 13Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 17Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly
Dec 05An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued
Oct 18Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?
Oct 06Shandong Weigao Group Medical Polymer (HKG:1066) Shareholders Will Want The ROCE Trajectory To Continue
Sep 10Shandong Weigao Group Medical Polymer (HKG:1066) Has A Rock Solid Balance Sheet
Aug 29Calculating The Fair Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Jul 09Here's Why I Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today
Jun 26Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥2b |
| Mar 31 2024 | n/a | n/a | CN¥2b |
| Dec 31 2023 | CN¥4m | CN¥2m | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥2b |
| Mar 31 2023 | n/a | n/a | CN¥3b |
| Dec 31 2022 | CN¥5m | CN¥950k | CN¥3b |
| Sep 30 2022 | n/a | n/a | CN¥3b |
| Jun 30 2022 | n/a | n/a | CN¥3b |
| Mar 31 2022 | n/a | n/a | CN¥2b |
| Dec 31 2021 | CN¥3m | CN¥903k | CN¥2b |
Rémunération vs marché: La rémunération totale de Rinan ($USD 559.03K ) est dans la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 505.05K ).
Rémunération et revenus: La rémunération de Rinan a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Rinan Cong (43 yo)
no data
Titularisation
CN¥3,990,000
Compensation
Mr. Rinan Cong served as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 until 2024 and served as Executive Director since May 24, 2021 until 2024 and...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chairman of the Board & Compliance Officer | 5.7yrs | CN¥8.27m | 0.14% CN¥ 28.6m | |
| Chief Executive Officer | no data | CN¥3.99m | 0.048% CN¥ 9.7m | |
| Executive Director | 2.2yrs | CN¥1.32m | pas de données | |
| Chief Financial Officer | 7.5yrs | pas de données | pas de données | |
| Non-Executive Director | less than a year | pas de données | pas de données | |
| Executive Director | less than a year | pas de données | 0.011% CN¥ 2.2m | |
| Company Secretary | 18.3yrs | pas de données | pas de données |
2.2yrs
Durée moyenne de l'emploi
49yo
Âge moyen
Gestion expérimentée: L'équipe de direction de 1066 est considérée comme expérimentée (ancienneté moyenne 2.2 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chairman of the Board & Compliance Officer | 5.7yrs | CN¥8.27m | 0.14% CN¥ 28.6m | |
| Executive Director | 2.2yrs | CN¥1.32m | pas de données | |
| Non-Executive Director | less than a year | pas de données | pas de données | |
| Executive Director | less than a year | pas de données | 0.011% CN¥ 2.2m | |
| Non-Executive Director | 3.4yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 1.9yrs | CN¥150.00k | pas de données | |
| Independent Non-Executive Director | 2.2yrs | CN¥207.00k | pas de données | |
| Vice Chairman | 3.4yrs | pas de données | pas de données | |
| Chairman of the Supervisors | 4.1yrs | pas de données | pas de données | |
| Employee Representative Supervisor | 2.3yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 1.7yrs | CN¥150.00k | pas de données | |
| Independent Non-Executive Director | less than a year | pas de données | pas de données |
2.2yrs
Durée moyenne de l'emploi
49yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de 1066 ne sont pas considérés comme expérimentés (ancienneté moyenne 2.2 ans), ce qui suggère un nouveau conseil d'administration.